Surgical and Oncological Outcomes of Robot-Assisted Radical Prostatectomy as Part of Multimodal Therapy for NCCN Very High-Risk Prostate Cancer: A Single-Institution Retrospective Analysis
This single-institution retrospective analysis demonstrates that robot-assisted radical prostatectomy as part of multimodal therapy for NCCN very high-risk prostate cancer yields favorable perioperative safety and long-term survival outcomes, with a non-significant trend toward improved progression-free survival in patients receiving neoadjuvant therapy.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Prostate cancer is a common disease for men, but not all cases are the same. Doctors group these cancers by how likely they are to grow quickly or spread to other parts of the body. At the most serious end of this scale sits "very high-risk" prostate cancer. This is a form of the disease that has already begun to extend beyond the prostate gland or shows signs of being particularly aggressive. Because these tumors are so dangerous, the standard approach has often been to combine surgery with powerful hormone treatments given before and after the operation. The goal is to shrink the tumor before cutting it out and then keep any remaining cells from growing back. However, finding the perfect recipe for combining these treatments has been difficult. While radiation therapy has long been a standard option, many doctors now turn to robotic surgery to remove the prostate, hoping it offers better control. The big question remains: does adding hormone therapy before or after this specific type of surgery actually help men with the most dangerous forms of the disease live longer or stay cancer-free?
A team of surgeons at Saiseikai Kumamoto Hospital in Japan set out to answer this question by looking back at their own recent work. They focused on 88 men who had very high-risk prostate cancer and underwent a robot-assisted radical prostatectomy, a procedure where a surgeon uses a robotic system with tiny instruments to remove the prostate gland through small incisions. The researchers wanted to see how safe the surgery was, how well the men recovered their daily functions, and whether adding hormone therapy before the surgery or after it made a difference in survival. They followed these patients for a median of about 44 months, tracking whether the cancer returned or if the men passed away from any cause.
The surgery itself proved to be remarkably safe and precise. The operations took a median of just under four hours, and the amount of blood lost was minimal, with a median of only 60 milliliters. This is a very small amount, roughly equivalent to a single shot glass. Even with the complex nature of removing a very high-risk tumor, the surgeons were able to preserve urinary control for most patients. By the end of the study, nearly three-quarters of the men were using fewer than one protective pad per day, a standard measure for functional continence. In terms of the cancer itself, the results were striking. Over the five-year period, no patient died from prostate cancer, and the overall survival rate was nearly 98 percent. This suggests that removing the tumor with this robotic approach, even in advanced cases, can be highly effective at controlling the disease.
However, the story becomes more nuanced when looking at the hormone treatments. The researchers divided the patients into groups based on whether they received hormone therapy before the surgery, after the surgery, both, or neither. They found that men who received hormone therapy before the operation had a slightly better chance of staying free of cancer recurrence compared to those who did not. Specifically, about 41 percent of the pre-treatment group remained cancer-free at five years, compared to about 27 percent of those who skipped the pre-treatment. While this difference looks promising, the study was not large enough to prove that this improvement was not just a coincidence. The data suggests a benefit, but it does not confirm it with absolute certainty.
The results for hormone therapy given after the surgery told a different story. Men who received treatment after the operation did not show a better survival rate than those who did not. In fact, their cancer recurrence rates looked slightly worse, though this was not a statistically significant difference. The researchers explained this by noting that doctors were more likely to prescribe post-surgery hormone therapy to the patients who had the most severe signs of cancer in their pathology reports. Because these patients started with a higher risk of the disease returning, the therapy did not appear to help them catch up to the lower-risk group. This highlights a common challenge in medical research: when doctors choose treatments based on how sick a patient is, it becomes hard to tell if the treatment itself is working or if the patients were just different to begin with.
Ultimately, this study provides a clear picture of what happens when very high-risk prostate cancer is treated with robotic surgery. The procedure is safe, preserves quality of life, and offers excellent survival rates when combined with a multimodal approach. The data hints that giving hormone therapy before the surgery might help delay the return of the cancer, but the evidence is not yet strong enough to declare it a guaranteed solution. The lack of a clear benefit from post-surgery therapy in this group seems to be a result of treating the sickest patients, rather than a failure of the treatment itself. The authors conclude that while their results are encouraging, larger studies with more patients and standardized treatment plans are needed to confirm exactly how best to combine these therapies for the men who face the most aggressive form of this disease.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.